Research programme: PDE3 inhibitors - Artesian Therapeutics

Drug Profile

Research programme: PDE3 inhibitors - Artesian Therapeutics

Alternative Names: 3QO4; ATI22-107; ATI24-214; heart failure therapeutics - Artesian Therapeutics; Type-3 phosphodiesterase inhibitors - Artesian Therapeutics; β-adrenoreceptor antagonists - Artesian Therapeutics

Latest Information Update: 03 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Artesian Therapeutics
  • Class Small molecules
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Heart failure

Most Recent Events

  • 28 Feb 2014 No development reported - Preclinical for Heart failure in USA (unspecified route)
  • 19 Apr 2006 This programme is still in active development
  • 27 Oct 2005 Artesian Therapeutics has been acquired by Cardiome Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top